Frost & Sullivan Independent Equity Research
DNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged.
Company: DNA Biomedical Solutions Ltd.
Report type: Q4-2017 and Annual 2017 Updates
Published on: 10 April, 2018